Pathway Genomics vs Emulate
Side-by-side comparison of AI visibility scores, market position, and capabilities
CAP- and CLIA-accredited clinical genetic testing lab offering cancer risk, cardiac, pharmacogenomics, and wellness panels to physicians and patients; privately held, San Diego, founded 2008.
About
Pathway Genomics (also known as Pathway OME) is a privately held clinical genetic testing company founded in 2008 and headquartered in San Diego, California. The company operates a CAP-accredited and CLIA-certified clinical laboratory that provides physicians and patients with actionable, precision healthcare information derived from genetic analysis. Pathway's testing services cover cancer risk assessment, cardiac health, pharmacogenomics (drug response), inherited disease risk, nutrition and exercise response, and reproductive health — enabling personalized healthcare decisions grounded in genetic data.
Pioneering organ-on-chip platform installed in 150+ labs including 17 of the top 25 biopharma companies; launched AVA™ high-throughput 96-chip system in 2025 and holds the only FDA ISTAND-accepted DILI Organ-Chip.
About
Emulate, Inc. is a Boston-based biotechnology company that designs, manufactures, and commercializes Organ-Chip technology — micro-engineered devices lined with living human cells that replicate the microstructure and function of human organs. Founded in 2013 as a spin-out from the Wyss Institute at Harvard University, Emulate's chips model the liver, intestine, lung, kidney, brain, and other organ systems with a fidelity that animal models and traditional cell culture cannot match. The technology was originally developed to reduce drug development attrition rates caused by poor translation from animal studies to human clinical outcomes.
AI Visibility Head-to-Head
Key Details
Also Compare
Track AI Visibility in Real Time
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.